Table 6.

Analysis of owner based assessments of client specific outcome measures (CSOM) total score and Feline Musculoskeletal Pain Index (FMPI) score.

Owner assessment	Estimate	SE	t value**	Pr >|t|	Effect size
CSOM total score
C1	0.49	0.52	0.95	0.34	0.09
C2	1.40	0.53	2.62	0.010*	0.33
C3	0.67	0.54	1.25	0.21	0.16
CSOM total score adjusted for baseline
C1	0.23	0.46	0.50	0.62	0.05
C2	0.94	0.46	2.04	0.044*	0.26
C3	0.60	0.54	1.13	0.26	0.14
FMPI score
C1	− 0.66	2.36	− 0.28	0.78	− 0.03
C2	4.65	2.58	1.80	0.075	0.18
C3	0.43	1.77	0.25	0.81	0.03
FMPI score adjusted for baseline
C1	− 2.66	1.86	− 1.43	0.15	− 0.12
C2	0.75	1.96	0.38	0.70	0.04
C3	0.75	1.77	0.42	0.67	0.04

Estimates show the effect of robenacoxib relative to placebo.

SE standard error, C1 contrast 1 = treatment group PP compared against groups RR and RP following 3 weeks of treatment, C2 contrast 2 = treatment group PP compared against group RR following 6 weeks of treatment, C3 contrast 3 = treatment group RP compared against RR for change in activity between weeks 3 and 6 of treatment. P = placebo; R = robenacoxib.

*Significance at 0.05 level.

**Student’s t statistic for testing whether the contrast equals zero; two-tailed test.